Rheumatology Practice Management June 2018 Vol 6 No 3
NORM is here to partner with you to chart a course of continued success and sustainability. Change is never easy, but in the rheumatology world, it is a constant. Preparing our physicians and staff to anticipate changes and effectively navigate them is part of our job as leaders within our practices.
Are you ready to take charge and navigate through the choppy seas of medical practice management? Overcoming this challenge is infinitely easier when you have access to the right tools and individuals who can show you how to use them.
The National Organization of Rheumatology Managers’ (NORM) journey into social media started approximately 5 years ago when I graduated from North Carolina State University with my Master’s degree in communications.
The most challenging job for the National Organization of Rheumatology Managers’ (NORM) Membership Committee is making the first contact with a practice. Once that contact has been made, and the committee member has the opportunity to explain all of the benefits of membership, the rest is easy.
New Hampshire Senate Bill 581 (SB581) was introduced into the New Hampshire Senate in January 2018. It amends the definition of “compounding” to preclude the preparation of a single dose of a nonhazardous, commercially available drug or licensed biologic for administration to an individual patient prepared in accordance with the manufacturer’s approved labeling.
Xeljanz/Xeljanz XR (Tofacitinib/Tofacitinib XR), an Oral JAK Inhibitor, Now Approved for Adults with Active Psoriatic Arthritis
Although psoriatic arthritis most often affects the distal joints in the fingers and toes, the disease can also affect the lower back, wrists, knees, and ankles.
Have you ever felt overwhelmed with the state of your practice and although you know that change is necessary, you have no idea where to begin? I often hear, “Our practice is so busy, and we have changes that must be made to report successful results to CMS for MIPS.
The first question attempted to broadly elicit ways to reduce the burden associated with the documentation of patient E&M visits. The second question was designed to gain input from attendees on approaches that other payers take to both payment and documentation regarding E&M visits.
Dr Doshi and colleagues used the study sample to predict what costs would have been using the MedPAC proposals and found that for patients using specialty RA drugs, the OOP costs would remain front loaded into the beginning of the year, ranging from $512 to $1076 per month from January to May.
The researchers observed that previous studies of dermatologic diseases have shown a much higher prevalence of depression in patients with CLE—in some cases double or triple that of the general population.
Page 1 of 2
Results 1 - 10 of 12
Results 1 - 10 of 12